In situ Gene Transfer and Suicide Gene Therapy of Gastric Cancer Induced by N‐Ethyl‐N′‐nitro‐N‐nitrosoguanidine in Dogs

Gene therapy could potentially revolutionize the treatment of gastrointestinal (GI) tract cancer. The aim of this study was to establish a practical method of gene transfer which would be applicable to human gastric cancer. Retrovirus or/and adenovirus vectors carrying the lacZ marker gene were transferred in situ by needle through an endoscopic biopsy channel into primary gastric cancer in six male beagle dogs that had been treated with N‐ethyl‐N′‐nitro‐N‐nitrosoguanidine (ENNG). In addition, an adenovirus vector carrying the herpes simplex virus thymidine kinase (Ad.CAGHSV‐TK) gene was introduced in situ into cancer tissues in the stomach of three dog, and the animals were treated with intravenous ganciclovir (GCV). Retrovirus‐producing cells which expressed the lacZ gene were specifically localized to the injection site in the stomach. The lacZ gene was more widely transferred into the tumor by the adenovirus vector than by retrovirus‐producing cells. Improvement of the needle used for gene transfer and the use of multiple injections per tumor led to more diffuse transfer of the vector into the tumor. The Ad.CAG lacZ gene was also transferred into regional lymph nodes of the stomach. Moderate to diffuse degeneration of the primary cancer tissues of the stomach was found after Ad.CAGHSV‐TK/GCV gene therapy. Moreover, almost complete tissue degeneration was observed in the regional lymph nodes of the stomach. An adverse effect of HSV‐TK/GCV gene therapy was acute hepatotoxicity, which was not found after Ad.CAG lacZ gene transfer, but was found after high‐titer Ad.CAGHSV‐TK gene transfer followed by GCV. These findings suggest that in situ gene transfer of a suicide gene followed by prodrug treatment may be applicable not only to primary tumors, but also to lymph node metastases of gastric cancer, though further study of both beneficial and adverse effects is required before clinical usage.

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  Y. Vergouwe,et al.  Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration , 1998, Gene Therapy.

[3]  M. Kurihara.  Inducement of canine gastric cancer by N-ethyl-N′-nitro-N-nitrosoguanidine (ENNG) , 1998, Gastric Cancer.

[4]  S. Yamamoto,et al.  Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice. , 1997, Cancer gene therapy.

[5]  Y. Shiratori,et al.  Adenovirus-mediated gene therapy of gastric carcinoma using cancer-specific gene expression in vivo. , 1997, Biochemical and biophysical research communications.

[6]  H. Wakimoto,et al.  Tumor-specific gene expression in carcinoembryonic antigen--producing gastric cancer cells using adenovirus vectors. , 1996, Gastroenterology.

[7]  C. Harris,et al.  Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. , 1996, Journal of the National Cancer Institute.

[8]  W. Hong,et al.  Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.

[9]  H. Wakimoto,et al.  Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. , 1996, Cancer research.

[10]  Y. Kanegae,et al.  Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Marrogi,et al.  In situ use of suicide genes for cancer therapy. , 1996, Seminars in oncology.

[12]  F. Nathan,et al.  Gene therapy for human cancer: an essay for clinicians. , 1996, Seminars in oncology.

[13]  Y. Kanegae,et al.  A simple and efficient method for purification of infectious recombinant adenovirus. , 1994, Japanese journal of medical science & biology.

[14]  K. Sikora,et al.  Gene therapy for cancer using tumour-specific prodrug activation. , 1994, Gene therapy.

[15]  S. Freeman,et al.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.

[16]  Kazutomo Inoue,et al.  Comparison of Survival Curves of Gastric Cancer Patients After Surgery According to the UICC Stage Classification and the General Rules for Gastric Cancer Study by the Japanese Research Society for Gastric Cancer , 1993, Annals of surgery.

[17]  A. Miller,et al.  Human gene therapy comes of age , 1992, Nature.

[18]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[19]  Y. Shimosato,et al.  Esophageal and gastric cancers with metastases induced in dogs by N-ethyl-N'-nitro-N-nitrosoguanidine. , 1977, Journal of the National Cancer Institute.

[20]  B. Dörken,et al.  Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. , 1997, Cancer gene therapy.

[21]  M Vapalahti,et al.  [Human gene therapy]. , 1996, Duodecim; laaketieteellinen aikakauskirja.

[22]  T. Blankenstein,et al.  Vectors in cancer therapy: how will they deliver? , 1995, Cancer gene therapy.

[23]  W F Anderson,et al.  Improved methods of retroviral vector transduction and production for gene therapy. , 1994, Human gene therapy.